Trial · NCT03541174
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement | Aprocitentan 12.5 mg in Part 1 (Double-blind) | -15.26 | 97.5% Confidence Interval -17.36 to -13.17 | mmHg | |
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement | Aprocitentan 25 mg in Part 1 (Double-blind) | -15.20 | 97.5% Confidence Interval -17.27 to -13.13 | mmHg | |
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement | Placebo in Part 1 (Double-blind) | -11.47 | 97.5% Confidence Interval -13.57 to -9.38 | mmHg | |
| Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | -1.47 | 95% Confidence Interval -2.97 to 0.04 | mmHg | |
| Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement | Placebo in Part 3 (Double-blind Withdrawal) | 4.36 | 95% Confidence Interval 2.87 to 5.85 | mmHg | |
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement | Aprocitentan 12.5 mg in Part 1 (Double-blind) | -10.43 | 95% Confidence Interval -11.58 to -9.27 | mmHg | |
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement | Aprocitentan 25 mg in Part 1 (Double-blind) | -10.95 | 95% Confidence Interval -12.09 to -9.82 | mmHg | |
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement | Placebo in Part 1 (Double-blind) | -6.48 | 95% Confidence Interval -7.63 to -5.33 | mmHg | |
| Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 24-hour mean systolic blood pressure | -6.73 | 95% Confidence Interval -8.20 to -5.26 | mmHg |
| Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Aprocitentan 25 mg in Part 1 (Double-blind) | 24-hour mean systolic blood pressure | -8.44 | 95% Confidence Interval -9.88 to -7.00 | mmHg |
| Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Placebo in Part 1 (Double-blind) | 24-hour mean systolic blood pressure | -2.55 | 95% Confidence Interval -4.00 to -1.10 | mmHg |
| Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 24-hour mean diastolic blood pressure | -6.25 | 95% Confidence Interval -7.20 to -5.29 | mmHg |
| Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Aprocitentan 25 mg in Part 1 (Double-blind) | 24-hour mean diastolic blood pressure | -7.74 | 95% Confidence Interval -8.67 to -6.80 | mmHg |
| Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Placebo in Part 1 (Double-blind) | 24-hour mean diastolic blood pressure | -1.92 | 95% Confidence Interval -2.87 to -0.98 | mmHg |
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | -0.52 | 95% Confidence Interval -1.54 to 0.50 | mmHg | |
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure | Placebo in Part 3 (Double-blind Withdrawal) | 4.67 | 95% Confidence Interval 3.66 to 5.68 | mmHg | |
Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 24-hour mean systolic blood pressure | -0.07 | 95% Confidence Interval -1.46 to 1.32 | mmHg |
Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Placebo in Part 3 (Double-blind Withdrawal) | 24-hour mean systolic blood pressure | 6.46 | 95% Confidence Interval 5.06 to 7.85 | mmHg |
Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 24-hour mean diastolic blood pressure | -0.47 | 95% Confidence Interval -1.34 to 0.40 | mmHg |
Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring | Placebo in Part 3 (Double-blind Withdrawal) | 24-hour mean diastolic blood pressure | 6.28 | 95% Confidence Interval 5.40 to 7.15 | mmHg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03541174/results